P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors

HIV Medicine

Volumn 4, Issue 1, 2003, Pages 67-71

  Bossi, Philippe ^a   Legrand, O ^b   Faussat, A M ^b   Legrand, M ^a   Bricaire, F ^a   Marie, J P ^b   Agut, H ^a   Diquet, B ^a   Katlama, C ^a   Huraux, J M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

Author keywords

HIV; P glycoprotein; Resistance

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN P; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; PROTEINASE; VIRUS RNA;

ARTICLE; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HELPER CELL; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; LYMPH NODE; MALARIA; MALE; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOLID TUMOR; TREATMENT FAILURE; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; BLOOD; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG COMBINATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METABOLISM; MUTATION; VIROLOGY; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; P-GLYCOPROTEIN; RNA, VIRAL; VIRAL LOAD;

EID: 0037264739     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00134.x     Document Type: Article

References (32)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
2. Gupta S, Gollapudi S. P-glycoprotein (MDR-1 gene product) in cells of the immune system: its possible physiolgic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993; 13: 289-301.
3. Kaye SB. Multidrug resistance: clinical relevance in solid tumors and strategies for circumvention. Curr Opin Oncol 1998; 10: S15-S19.
4. Ullman B. Multidrug resistance and P-glycoproteins in parasitic protozoa. J Bioenerg Biomembr 1995; 27: 77-84.
5. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996; 32: 1034-1038.
6. Drach D, Zhao S, Drach J et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729-2734.
7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localisation of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
8. Andrena A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, Gupta S. Abnormal expression of a 170-Kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retrovir 1996; 12: 157-162.
9. Gollapudi S, Gupta S. Human immunodeficiency virus 1 induced expression of P-glycoprotein. Biochem Biophys Res Commun 1990; 171: 1002-1007.
10. Huisman M, Smit J, Schinkel A. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237-242.
11. Lee CG, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter. Biochemistry 1998; 37: 3594-3601.
12. Lee C, Gottesman M. HIV-1 protease inhibitors and the MDR-1 multidrug transporter. J Clin Invest 1998; 101: 287-288.
13. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286: 1439-1445.
14. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharmacol Res 1998; 15: 423-428.
15. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-389.
16. Clayette P, Jorajuria S, Dormont D. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 235-236.
17. Srinivas RV, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemoter 1998; 42: 3157-3162.
18. Lee C, Ramachandra M, Jeang K, Martin M, Pastan I, Gottesman M. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 2000; 14: 516-522.
19. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13: 1623-1627.
20. Polli JW, Jarret JL, Studenberg SD et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharmacol Res 1999; 16: 1206-1212.
21. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF Interaction of anti-HIV protease with the multidrug transporter P-glycoprotein (P-glycoprotein) in human cultured cells. J Acquir Immun Defic Syndr Hum Retrovirol 1998; 19: 203-209.
22. Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
23. Myers G, Josephs SF, Rabson AB, Smith TF, eds. Clade B consensus. In: Human Retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos.
24. Beck WT, Grogan TM, Willman CL et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: consensus recommendations. Cancer Res 1996; 56: 3010-3020.
25. Marie JP, Huet S, Faussat AM et al. French network of the drug resistance intergroup, and drug resistance network of Assistance Publique-Hôpitaux de Paris: multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997; 11: 1095-1106.
26. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP ativities using calcein-AM are prognostic factors in adults AML patients. Blood 1998; 91: 4480-4488.
27. Richman D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993; 37: 1207-1213.
28. Sommadossi JP, Zhou XJ, Moore J. Impairment of stavudine phosphorylation in patients receiving a combination of zidovudine and D4T. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 1998 [Abstract 3].
29. Speck R, Krithivas A, Hamzeh A et al. Effect of stavudine and zidovudine on expression of the P-glycoprotein drug transporter in HIV-1 infected patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000 [Abstract 97].
30. Leung S, Bendayan R. Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs. Can J Physiol Pharmacol 1999; 77: 625-630.
31. Legrand O, Perrot JY, Simonin G, Baudard M, Marie JP. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood, 2001; 97: 502-508.
32. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA. Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia 1997; 11: 1147-1153.